pharmaphorum

NOVEMBER 23, 2021

The French drugmaker has been enticed by an artificial intelligence (AI) algorithm developed by Chinese tech giant Baidu, which controls most of China’s search engine traffic and is sometimes referred to as the country’s Google. billion earlier this year.

Licensing 105

Licensing Licensing Vaccine Vaccination 105

Pharmaceutical Technology

AUGUST 12, 2022

The concept behind this form of treatment is that the introduction of these cells will enhance the immune response to disease, often through bioengineering the immune cells to have improved functionality and characteristics, such as longer half-lives. There are also 19 drugs in preclinical development (Table 1).

Development 130

Development Drugs Immune Response Marketing 130

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Vaccine 116

Vaccine Vaccination Clinical Trials Clinical Trials 116

XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Cell-Based Immunotherapy vs. Immune Biologics. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

NOVEMBER 30, 2023

New FDA-Approved Treatments For HIV HIV treatment involves the administration of combined antiretroviral therapy (ART) to effectively suppress the viral load, maintain or enhance immune function and reduce the risk of opportunistic infections and cancers commonly associated with HIV. percent in the placebo group.

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

The Pharma Data

DECEMBER 17, 2020

Merck will select cancer targets and harness Janux’s proprietary Tumor Activated T Cell Engager (TRACTr) technology to engineer novel, T cell engager drug candidates. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response. million per target, the company said.

Immune Response 52

Immune Response Engineer Development Licensing 52

Cloudbyz

MARCH 6, 2024

Traditionally, pharmaceutical therapies have primarily consisted of small molecule drugs, commonly known as pills. This shift signifies not just a change in the way drugs are manufactured and administered, but also a fundamental transformation in the approach to treating diseases at their root cause.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

BioTech 365

OCTOBER 22, 2020

-Proof-of-concept achieved for VY-UC to engineer donor cells without the complexities of gene-editing -Novel platform abrogates cellular immune response and obviates the need for immunosuppressive drugs TAMPA, Fla. & & STOCKHOLM–(BUSINESS WIRE)–#celltherapy–Vycellix, Inc.,

Gene Editing 40

Gene Editing Immune Response Life Science Engineer 40

pharmaphorum

JANUARY 17, 2023

Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech Elicio Therapeutics. Darrell Irvine.

Immune Response 93

Immune Response Trials Engineer Sales 93

pharmaphorum

SEPTEMBER 11, 2022

The patient then receives chemotherapy to reduce regulatory T cells that can put a brake on immune responses to tumours, as well as immune-boosting cytokine interleukin-2, before the TILs are then reinfused into the patient intravenously. months versus 3.1 months with Yervoy, which was a significant improvement.

Trials 105

Trials Genetic Engineering Immune Response Engineer 105

pharmaphorum

APRIL 26, 2022

The treatment has been granted US FDA breakthrough therapy designation and orphan drug designation, and has also completed a phase 3 clinical study. The biotech is eligible to receive a further $125 million if the FDA approves the drug and could receive another $225 million in commercial milestones. difficile infection (CDI).

Containment 115

Containment Development Production Drugs 115

pharmaphorum

OCTOBER 12, 2022

Having spent 10 years working in the genomics field, Del Bourgo noticed manufacturers spending extensive resources on drug development without harnessing the transformative power of data. We have analysed this area extensively and Whitelab Genomics is one the best companies that we have identified.”. “We

Genomics 105

Genomics Genome Medicine Development 105

The Pharma Data

NOVEMBER 22, 2020

Pandion focuses on the development of innovative modular therapeutics using its TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform. The TALON effector modules are based on immunomodulatory molecules that act as regulatory control points within the immune system.

Antibody 52

Antibody Immune Response Engineer Protein 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. Additional terms of the agreement were not disclosed. About NVX-CoV2373. About Novavax. Novavax, Inc.?(Nasdaq:

Protein 52

Protein Vaccination Vaccine Immune Response 52

pharmaphorum

FEBRUARY 25, 2021

billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101. . The first trial showed that it could increase levels of Treg cells thought to be involved in dampening down immune responses. Merck & Co/MSD has agreed to buy Pandion for $1.85

Clinical Trials 71

Clinical Trials Clinical Trials Immune Response Trials 71

Roots Analysis

MAY 21, 2024

Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

The Pharma Data

AUGUST 22, 2021

A review of the survivors’ medical records revealed that a significant number suffered from chronic heartburn and were taking an inexpensive drug called famotidine, the key ingredient in Pepcid. Wealthier patients tended to take the more costly drug omeprazole, found in Prilosec.).

Doctors 52

Doctors Doctor Drugs Scientist 52

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 1.351 variant.

Protein 97

Protein Vaccination Vaccine Trials 97

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. CAMBRIDGE, Mass. , Sokolovska, A.,

Immune Response 40

Immune Response Engineer Medicine Clinical Trials 40

The Pharma Data

JANUARY 17, 2021

Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days. The data showed that the vaccine induced an immune response and was generally well-tolerated.

Immune Response 52

Immune Response Antibody Trials Clinical Trials 52

pharmaphorum

NOVEMBER 29, 2022

T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. Dr Yang has created several intellectual-property protected inventions, including the hyFc® platform technology and NT-I7 drug candidate. NT-I7 (efineptakin alfa).

Clinical Trials 105

Clinical Trials Clinical Trials Trials Engineer 105

pharmaphorum

SEPTEMBER 7, 2022

.” Roche’s activity in this area is represented by RG6279, an anti-PD-1 antibody fused to an engineered, variant form of IL-2 which is in phase 1 clinical testing. Good’s lead drug is due to start clinical testing next year.

Immune Response 52

Immune Response Engineer Clinical Trials Clinical Trials 52

pharmaphorum

JANUARY 7, 2021

Used with widely available PET scan technology, ImaginAb’s technology allows doctors to track the T-cell immune response to cancer in real time and it has already picked up a multi-party deal involving Pfizer, AstraZeneca and Takeda.

Immune Response 53

Immune Response Doctors Doctor Pharma Companies 53

The Pharma Data

APRIL 8, 2021

Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1. Kenilworth, NJ, USA (known as MSD outside the U.S. About THOR-707 (SAR444245).

Immune Response 52

Immune Response Engineer Antibody Genetics 52

The Pharma Data

JANUARY 12, 2021

“KSQ’s CRISPRomics discovery platform is a powerful technology to help us identify novel targets in line with our immuno-oncology strategy,” said Loïc Vincent, Head, Oncology Drug Discovery Unit and Immunology Unit at Takeda.

Development 52

Development Research In-Vivo Genomics 52

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. GAITHERSBURG, Md., 09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

XTalks

FEBRUARY 29, 2024

These innovative molecules are engineered by combining two or more functional domains from different proteins into a single, cohesive unit, enabling them to perform multiple biological activities simultaneously. Preclinical comparisons with magrolimab showed our drug had higher response rates and longer-lasting effects.

Protein 94

Protein Development Clinical Trials Clinical Trials 94

The Pharma Data

JANUARY 17, 2021

a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology portfolio. . Immuno-oncology is a leading research priority because it uses the body’s own immune system to effectively treat some types of cancer. RENSSELAER, N.Y.,

Genetic Engineering 40

Genetic Engineering Genetics Engineer Immune Response 40

pharmaphorum

JANUARY 4, 2023

The University of Michigan spinoff’s NanoDisc technology relies on the use of synthetic, high-density lipoproteins that can be engineered to carry a payload of antigens, presenting them for recognition by the immune system – specifically, dendritic cells within lymph nodes.

Immune Response 52

Immune Response Engineer Licensing Licensing 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Freenome’s diagnostic searches for direct indication of tumors and signs of the immune system’s response, integrating genomics, transcriptomics, methylomics, and proteomics technologies.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

AUGUST 15, 2021

Now, researchers reporting in ACS Central Science have immunized mice with nanoparticles that mimic SARS-CoV-2 by displaying multiple copies of the receptor binding domain (RBD) antigen, showing that the vaccine triggers robust antibody and T cell responses. Although the first vaccines to receive Emergency Use Authorization by the U.S.

Protein 52

Protein Vaccination Vaccine Antibody 52

The Pharma Data

JUNE 1, 2022

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Previous research has shown that caspase 11 in mice has many of the same immune-response functions as caspase 4 in humans.

Immune Response 52

Immune Response Genetic Engineering Research Engineer 52

The Pharma Data

APRIL 22, 2023

While no cure is available for MS, existing disease-modifying therapies in the form of small molecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation. Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A.

Immune Response 40

Immune Response Engineer In-Vivo Containment 40

Advarra

JANUARY 11, 2024

Additionally, personalized medicine tends to be more difficult to manufacture because of regulatory requirements beyond traditional drug manufacturing requirements. Adoptive T Cell Therapies Adoptive T cell therapy is another form of cancer treatment leveraging the patient’s immune system.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

The Pharma Data

OCTOBER 21, 2020

Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-001, an allogeneic gamma delta (??) We are particularly excited to advance on our goal to exploit the therapeutic potential of our first in class engineered CAR ?? T cell therapy in NHL patients. About Adicet.

Immune Response 40

Immune Response Engineer Clinical Trials Clinical Trials 40

XTalks

MAY 24, 2024

The US Food and Drug Administration (FDA) has approved Amgen’s Imdelltra (tarlatamab-dlle) for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in patients who have experienced disease progression after platinum-based chemotherapy. About 40 percent of patients saw significant shrinkage.

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

XTalks

DECEMBER 12, 2023

It’s all part of a deep-seated commitment to innovation and its role as the company’s growth engine. These therapies consist of thousands of antibodies that are made in the laboratory versus being extracted from plasma, to treat disease with a diverse response, the same way a natural immune system would.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111